Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Ligand Pharmaceuticals (LGND) Share Price
News articles about Ligand Pharmaceuticals (NASDAQ:LGND) have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.4845294087365 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Ligand Pharmaceuticals (LGND) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- Ligand Pharmaceuticals Inc. (LGND) CEO Sells $1,413,270.00 in Stock (americanbankingnews.com)
- Ligand Pharmaceuticals Just Within Buy Range As Quarterly Report Nears (investors.com)
- Ligand Pharmaceuticals (LGND) to Release Quarterly Earnings on Wednesday (americanbankingnews.com)
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) opened at $155.51 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.95 and a current ratio of 0.97. Ligand Pharmaceuticals has a 52 week low of $95.08 and a 52 week high of $170.30. The company has a market cap of $3,280.00, a PE ratio of 225.38, a price-to-earnings-growth ratio of 1.68 and a beta of 1.07.
In other Ligand Pharmaceuticals news, CEO John L. Higgins sold 22,500 shares of the company’s stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $165.00, for a total transaction of $3,712,500.00. Following the completion of the sale, the chief executive officer now directly owns 111,700 shares of the company’s stock, valued at $18,430,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John L. Higgins sold 28,099 shares of the company’s stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $153.70, for a total transaction of $4,318,816.30. Following the sale, the chief executive officer now directly owns 162,299 shares of the company’s stock, valued at $24,945,356.30. The disclosure for this sale can be found here. Insiders have sold 63,024 shares of company stock valued at $9,934,043 over the last ninety days. Insiders own 8.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Ligand Pharmaceuticals (LGND) Share Price” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2018/02/21/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-ligand-pharmaceuticals-lgnd-share-price.html.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.